Biosig Technologies (NYSE:BSGM)‘s stock had its “buy” rating reaffirmed by stock analysts at Roth Capital in a report issued on Thursday.

Shares of BSGM stock traded down $0.09 during mid-day trading on Thursday, reaching $3.92. 21,572 shares of the company’s stock traded hands.

About Biosig Technologies

BioSig Technologies, Inc, a development stage medical device company, engages in developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Its product is PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes, and displays electrocardiogram and electrograms required during electrophysiology studies and catheter ablation procedures.

Recommended Story: What is systematic risk?

Receive News & Ratings for Biosig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.